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Abstract
Background: The development of a patient-reported outcome measure (PROM) for polymyalgia rheumatica (PMR),
a condition that causes pain, stiffness and disability, is necessary as there is no current validated disease-specific
measure. Initial literature synthesis and qualitative research established a conceptual framework for the condition
along with a list of symptoms and effects of PMR that patients felt were important to them. These findings were
used to derive the candidate items for a patient-completed questionnaire. We aim to establish the face validity of
this initial “long form” of a PROM.
Methods: People with a current or previous diagnosis of PMR were recruited both from the community and from
rheumatology clinics. They were asked to complete the PMR questionnaire along with the QQ-10 questionnaire,
which is a measure used to assess the face validity, feasibility and utility of patient healthcare questionnaires.
Results: A total of 28 participants with an age range of 59–85 years and a length of time since diagnosis from
4 months to 18 years completed the QQ-10. The overall mean “value” score was 79% (SD 12), and the mean “burden”
score was 21% (SD 18). The free-text comments were analysed thematically and were found to focus on layout,
content, where in the clinical pathway the questionnaire would be most beneficial, specific items missing and other
areas for consideration.
Conclusions: The high mean value score and low burden score indicate that the questionnaire has good face validity
and is acceptable to patients. The questionnaire now needs to undergo further psychometric evaluation and refinement
to develop the final tool for use in clinical practice and research.
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Background
Polymyalgia rheumatica (PMR) causes significant pain,
stiffness and disability in older adults and is treated
with systemic glucocorticoids which can themselves
cause significant additional morbidity [1, 2]. A recent
systematic review of outcome measures used in PMR
research studies [3] identified a wide variety of instru-
ments in use, none of which were specifically devel-
oped to measure symptom burden in patients with
PMR. Less than 10% of studies measured physical
function, quality of life or fatigue, despite these being
important to patients [4]. Further work, including a
Delphi survey conducted by the OMERACT PMR
Working Group, highlighted the need for a disease-
specific outcome measure that would cover domains
of life impact relevant to patients [5]. Applying inter-
national guidelines for patient-reported outcome
measure (PROM) development [6], we carried out ini-
tial qualitative work with patients with PMR to better
understand patient experience of the condition and
establish a conceptual framework for a future PMR
PROM [7]. Here, we report the next steps taken to
derive a “long-list” of candidate items for a PMR-
specific PROM and the assessment of face validity,
feasibility and utility both in the participants of the
original study and in a separate group of patients,
using a validated method, the QQ-10 questionnaire
[8]. The QQ-10 is a measure developed to collect
standardised information on important aspects of a
questionnaire’s qualities from the patient’s perspective
and is used to assess the face validity, feasibility and
utility of patient healthcare questionnaires. This part
of the iterative PROM development process is par-
ticularly important to ensure that the instrument is
acceptable and contains the content that is relevant
to patients with PMR, and completion burden of the
final questionnaire is minimised thus improving
follow-up and questionnaire completion rates in clin-
ical trials [9]. These data are vital for development of
a PROM that is valid for either research studies or
clinical practice.
Methods
A long-list of candidate items for the PROM was
developed from the data obtained from a previous
qualitative study carried out by our group [7]. These
items were categorised into main symptoms/duration
(4 items), function (24 items), emotional and psycho-
logical well-being (11 items), steroid side effects (10
items) and overall well-being (1 item). Respondent
validation of the themes and items was carried out
with the original interview participants. All 20 inter-
viewees from the qualitative study were sent a copy
Table 1 Long-list of PMR PROM questionnaire items derived
from the qualitative study
Item Question
1 How severe has the pain from your PMR been in the last 2 weeks?
(0-10 visual analogue scale (VAS) with 0 = no pain and 10 = the worst pain
you’ve ever had)
2 How severe has the stiffness from your PMR been in the last 2 weeks?
(0-10 VAS with 0 = no stiffness and 10 = the worst stiffness you’ve ever felt)
3 How severe has the weakness from your PMR been in the last 2 weeks?
(0-10 VAS with 0 = no weakness and 10 = complete weakness)
4 On average, for how much of each day has the pain/stiffness/weakness from
your PMR been present for during the last 2 weeks?
All day/About half the day/Around 1-3 hours/< 1 hour
5 FUNCTION: Over the last 2 weeks, compared to what you can normally do,
has PMR limited your ability to do the following activities?
Graded as 1) no, not limited at all, 2) yes, limited a little, 3) yes, limited a lot,
4) not relevant
Bend down
Get up after bending down
Get in and out of a car
Drive a car
Get in and out of bed
Get in or out of a chair
Get in or out of a bath
Wash yourself fully
Dry yourself fully after a shower/bath
Take your coat on or off
Put on or take off your socks and shoes
Comb or blow dry your hair
Get on or off the toilet
Wipe yourself after going to the toilet
Engage in intimate/sexual activity
Walk up stairs
Walk up hills
Walk on the flat
Carry or lift things
Reach above your head for things
Grip objects
Do housework
Do gardening
Sit for more than 30 minutes at a time
Participate in sports
6 EMOTIONAL AND PSYCHOLOGICAL WELL-BEING: In the last 2 weeks have
your PMR symptoms…
Graded as 1) none of the time, 2) a little of the time, 3) some of the time,
4) most of the time, 5) all of the time
Caused you to feel low in mood
Caused you to feel anxious
Caused you to feel vulnerable
Lowered your self-confidence
Made you worried that you might fall over
Caused you to need more help with looking after yourself
Made you less inclined to go out
Stopped you doing hobbies that you used to do
Made you worry about the future
Affected your sleep
Made you feel more tired than usual
7 TREATMENT SIDE EFFECTS: How much have you been affected by side
effects from your medication in the last 2 weeks? (VAS with 0 = unaffected,
10 = severely affected)
8 In the last 2 weeks, have you been bothered by any of the following side
effects of your steroid medication? (Yes/No)
Weight gain
Change in appearance (fatter face, saggy skin)
Irritability
Low mood
Euphoria
Hyperactivity
Easy bruising
Indigestion
Insomnia
Hair loss
9 Do you feel back to the level of health you were at before you first
experienced PMR symptoms? (Yes/No)
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of the long-list and asked to return it with any com-
ments that they had on the content. Ten of these in-
dividuals agreed to a structured telephone interview
to discuss the long list in more detail and the infor-
mation gathered from this was used to make changes
to it to form the draft questionnaire (Table 1).
To assess face validity and utility in an independent
group of patients, patients with a diagnosis of PMR
were recruited through two routes: (1) community-
based: through a patient-led patient support group,
PMR&GCAUK North East Support and (2) hospital-
based: through rheumatology clinics at Leeds Teaching
Hospitals NHS Trust. This recruitment strategy was de-
signed to sample from the full spectrum of patients with
PMR as it is a condition managed in both primary and
secondary care. Ethical approval was received from the
National Institute for Social Care and Health Research
Research Ethics Service, Wales REC 7 (Ref 12/WA/0344),
and all participants provided informed consent. Patients
received the study materials by post (community-based re-
cruitment) or in a sealed envelope from their treating
rheumatologist (hospital-based recruitment), completed
the study materials at home in their own time, and
returned the completed forms to the lead researcher
(HT), who was based at a different institution and in a dif-
ferent city to their rheumatology clinic.
The data from the QQ-10 questionnaire were analysed
both quantitatively and qualitatively. For quantitative
analysis we used the QQ-10 scoring method [8]. Likert
ratings from strongly disagree to strongly agree (coded
Fig. 1 Mean value of domains contributing to the value score
Fig. 2 Mean value of domains contributing to the burden score
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as 0–4) were summed separately for the first six ques-
tions comprising the value score (helped me communi-
cate about my condition, relevant to my condition, easy
to complete, included all the aspects of my condition I
am concerned about, was enjoyable, would be happy to
complete as part of routine care), and from the last four
questions comprising the burden score (too long, embar-
rassing, complicated, upset me).
Qualitative thematic analysis [10] was performed on
comments received in response to the three free-text
questions at the end of the QQ-10:
1. Do you have any comments or suggestions on how
the questionnaire you used could be improved
(e.g., its structure, appearance or design)?
2. Were any of your important symptoms, problems or
concerns missed out by the questionnaire you used?
3. Do you feel that any areas or problems in the
questionnaire you used were over-represented?
Results
Twenty-eight patients took part (20 female and 8 male;
age range 59–85 years; duration since PMR diagnosis
4 months to 18 years; apart from a single participant
who was 18 years post diagnosis, no patient was more
than 5 years post diagnosis). Eighteen of the participants
were still on steroid treatment for their PMR.
The overall mean value score was 79% (SD 12), and
the mean burden score was 21% (SD 18). The median of
each domain making up the value score was >2 (range
0–4), and the median of each domain making up the
burden score was <1.5 (range 0–4). Figures 1 and 2 show
the median scores for each question, and Fig. 3 shows
the spread of responses for each question.
The five emergent themes from the free-text com-
ments (Table 2) were (1) layout, (2) content, (3) where
in the clinical pathway the questionnaire would be most
beneficial, (4) specific items not covered and (5) other
areas for consideration for inclusion. The content theme
encompassed sub-themes of depth and detail, specificity
to PMR and heterogeneity of the condition.
Discussion
This study represents a distinct, patient-orientated
phase within a stepped standardised methodological
approach to developing a PROM for PMR for re-
search and clinical practice. The use of the validated
QQ-10 measure is an example of how to embed pa-
tient perspectives at all stages within the PROM de-
velopment process, moving beyond the paradigm of
clinician-orientated outcome measures.
The high value and low burden scores are encouraging
as regards face validity and feasibility of the question-
naire. They are similar to scores obtained when the QQ-
10 has been used in other studies, including evaluation
of the King’s Health Questionnaire [11] and evaluation
of use of a bladder diary [12], and both of these tools
were judged as having been proven to be useful based
on these results. The free-text comments provided
added richness to the response data, and their analysis
highlights some important required amendments to the
structure and layout of the questionnaire as well as sug-
gesting some additional points for inclusion. The com-
ments related to content echo some of the findings from
our earlier qualitative work [7] and some of the known
challenges of outcome measurement in PMR, chiefly the
heterogeneity of the condition, difficulty in assessment
in the presence of co-morbidities and overlap with other
conditions [1, 4, 13].
The strengths of this study include the use of a vali-
dated instrument (QQ-10) to assess face validity, feasi-
bility and utility of instruments designed to assess the
life impact of particular disease states. The QQ-10 itself
was rigorously developed using standard psychometric
methods and has been demonstrated to have high
Fig. 3 Frequency distribution of scores for each question in the QQ-10
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Table 2 Thematic analysis of the QQ10 free-text answers
Theme Sub-theme Quote
Layout “I think it’s well set out in a fairly simple and effective format.”
“Where the table goes over the page, it would be helpful to repeat
the headers. Page numbering would be helpful.”
“Sheets should be numbered and column headings should be repeated
where they go onto 2 pages.”
“Questions about age etc. should be at the start.”
“Figure diagrams are a more direct indication of the type and location of
pain than the written word.”
Content Depth and detail “Too much detail, cut down on the number of boxes, they overlap too much.
Q5 has too many choices.”
“Seems quite straightforward.”
“Q9 (Do you feel back to the level of health you were at before you had PMR?)
- if answer is no, ask why?”
Specificity to PMR “PMR is not that specific. For me I sometimes ache and sometimes feel a
bit down. Muscle power has diminished but that may be age.”
“Many things you ask could be for other reasons such as depression, arthritis,
cancer etc. it’s not all PMR.”
“Some info on other conditions should be included e.g., I had had a stroke
previously and PMR imposed symptoms on top of those resulting from that.”
“Some symptoms (like weakness and difficulty reaching things in cupboards)
I already had from a shoulder injury it’s difficult to tell whether the PMR made
it worse or not.”
“As everyone is different there should be room for an individual’s particular
symptoms and concerns.”
“Q9 is irrelevant, no-one gets back to feeling as well as before.”
Heterogeneity “Should pain/ache be quantified? Different people will have different meanings.”
“Some questions didn’t seem to fit my symptoms but I don’t think I’m very
severely affected - time will tell.”
“PMR affects all of us in different ways and the questionnaire covers all aspects
and does no harm even if some questions overlap.”
Where in the clinical pathway
it would be most beneficial
“I think it’s an excellent questionnaire from the outset of a PMR diagnosis to a
record of the PMR journey.”
“I think the questionnaire will be very helpful, especially to people at the
beginning of their treatment when they probably have all of the problems listed.
I would have been reassured
to think the doctors knew how I was feeling.”
Specific items missing “The side effects of prednisolone”
“Diabetes, fluid retention leading to lymphoedema”
“The area of pain”
“More questions about fatigue could be included. Skin/hair condition missed out.”
“Swelling of the joints is not mentioned (hands, wrists, feet and ankles).”
“No real questions about where the pain was or what I couldn’t do.”
“One of my main concerns at the start was inability to fasten my own bra - had to
ask for help.”
Other concerns that could be included “Concerns about recurrence are important.”
“You might like to know how the steroid treatment has helped/been successful.”
“It may be helpful to ask patients to put down aspects of their health that may not be
PMR related but which they wish to discuss.”
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internal consistency and item correlation and to be ac-
ceptable and understandable to patients [8]. It also has
the advantages of being quick and cheap to administer
and allowing comparison of different versions of a meas-
ure at several stages during development. At this stage
of questionnaire development, we made the decision not
to employ interview-based qualitative methods, such as
cognitive interviewing, as the postal method of respond-
ing did not exclude patients too frail to participate in
cognitive interviews, and allowed patients to respond
honestly, in private and without any concern that the re-
sponses might be seen by their treating clinicians. A fur-
ther strength of this study was the use of a combination
of recruitment methods which identified patients with a
range of disease durations similar to that described in
previous literature [14, 15].
The main limitation of this study was the small num-
ber of participants and opportunistic (and thus not sta-
tistically representative) sampling method. However, this
sample size was appropriate for this stage of PROM de-
velopment [16, 17]. A further limitation of this study
was that the community-based method of recruitment
required patients to self-identify as being diagnosed with
PMR. We did not attempt to validate diagnosis by means
of classification or other criteria designed to select pa-
tients with PMR for research studies, because we wanted
to assess this questionnaire in a real-life setting for clin-
ical practice, not just for use in research studies.
Conclusions
The long form of our PMR questionnaire was shown
to have face validity for patients and be acceptable
for use in their care. The work reported here repre-
sents an essential step in the PROM development
process, paving the way for further work using a lar-
ger sample size that will allow formal psychometric
validation, item reduction and ultimately generation
of a fully validated patient-reported outcome measure
for PMR.
Abbreviations
OMERACT: Outcome measures in rheumatology (www.omeract.org). An
independent initiative of international health professionals interested in
outcome measures in rheumatology; PMR: Polymyalgia rheumatica;
PROM: Patient-reported outcome measure
Acknowledgements
We would like to thank all of the study participants and the trustees and
members of PMR&GCA UK North East Support for their continued support
and cooperation.
Funding
This work was funded by a National Institute for Health Research (NIHR)
In-Practice Fellowship and a Royal College of General Practitioners Scientific
Foundation Board grant awarded to Helen Twohig.
CDM is funded by the National Institute for Health Research (NIHR)
Collaborations for Leadership in Applied Health Research and Care West
Midlands, the NIHR School for Primary Care Research and a NIHR Research
Professorship in General Practice (NIHR-RP-2014-04-026). The views expressed
are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
Availability of data and materials
The datasets generated and used during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
All authors contributed to the design of the study and contributed critically
to the content of the final manuscript. HT organised the data collection,
carried out the qualitative and quantitative analysis and drafted the initial
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was received from the National Institute for Social Care and
Health Research Research Ethics Service, Wales REC 7 (Ref 12/WA/0344), and
all participants provided informed consent.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Academic Unit of Primary Medical Care, University of Sheffield, Samuel Fox
House, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.
2Faculty of Health and Social Sciences, Leeds Beckett University, Leeds, UK.
3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of
Leeds, Leeds, UK. 4Arthritis Research UK Primary Care Centre, Institute for
Primary Care and Health Sciences, Keele University, Keele, UK. 5Academic
Unit of Primary Medical Care, University of Sheffield, Sheffield, UK.
Received: 28 February 2017 Accepted: 31 May 2017
References
1. Mackie SL, Mallen CDM. Polymyalgia rheumatica. BMJ. 2013;347:f6937.
2. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the
management of polymyalgia rheumatica. A European League Against
Rheumatisim/American College of Rheumatology Collaborative Initiative.
Ann Rheum Dis. 2015;74:1799–807.
3. Duarte C, Ferreira JO, Mackie SL, et al. Outcome measures in polymyalgia
rheumatica. A systematic review. J Rheumatol. 2015;42(12):2503–11.
4. Mackie SL, Arat S, da Silva J, et al. Polymyalgia rheumatica (PMR) special
interest group at OMERACT 11: outcomes of importance for patients with
PMR. J Rheumatol. 2014;41(4):819–23.
5. Helliwell T, Brouwer E, Pease CT, et al. Development of a provisional core
domain set for polymyalgia rheumatica: report from the OMERACT 12
polymyalgia rheumatica working group. J Rheumatol. 2016;43(1):182–6.
6. U.S. Dept of Health and Human Services Food and Drug Administration.
Guidance for industry: patient-reported outcomes measures: use in
medicinal product development to support labelling claims. 2009. http://
www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/UCM193282.pdf. Accessed 1 July 2016.
7. Twohig HJ, Mitchell CM, Mallen CDM, et al. “I suddenly felt I’d aged”: a
qualitative study of patient experiences of polymyalgia rheumatica (PMR).
Patient Educ Couns. 2015;98:645–50.
8. Moores KL, Jones GL, Radley SC. Development of an instrument to measure
face validity, feasibility and utility of patient questionnaire use during health
care: the QQ-10. Int J Qual Health Care. 2012;24:517–24.
9. Prescott RJ, Counsell CE, Gillespie WJ, et al. Factors that limit the quality,
number and progress of randomised controlled trials. Health Technol
Assess. 1993;3(20):1–143.
Twohig et al. Pilot and Feasibility Studies  (2018) 4:7 Page 6 of 7
10. Boyatzis RE. Transforming qualitative information: thematic analysis and
code development. Thousand Oaks, London, & New Delhi: SAGE
Publications; 1998.
11. Vij M, Srikrishna S, Robinson D, et al. Quality assurance in quality of life
assessment—measuring the validity of the King’s Health Questionnaire. Int
Urogynaecol J. 2014;25(8):1133–5.
12. Vella M, Robinson D, Cardozo L, et al. The bladder diary: do women perceive it
as a useful investigation? Eur J Obstet Tynecol Reprod Biol. 2012;162(2):221–3.
13. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional
classification criteria for polymyalgia rheumatica: a European League Against
Rheumatism/American College of Rheumatology collaborative initiative.
Ann Rheum Dis. 2012;71:484–92.
14. Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with
polymyalgia rheumatica and giant cell arteritis. J Rheumatol. 1998;25(1):99–104.
15. Mackie SL, Hensor EM, Haugeberg G, et al. Can the prognosis of
polymyalgia rheumatic be predicted at disease onset? Results from a 5-year
prospective study. Rheumatology. 2009;49(4):716–22.
16. Jones G, Kennedy S, Barnard A, et al. Development of an endometriosis
quality-of-life instrument: The Endometriosis Health Profile-30. Obstet
Gynecol. 2001;98(2):258–64.
17. Mirzaee Rabor F, Taghipour A, Mirzaee M et al. Developing a questionnaire
for Iranian women’s attitude on medical ethics in vaginal childbirth. Nurs
Midwifery Stud 2015 Dec;4(4):e29004. http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4733499/. Accessed 1 Jul 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Twohig et al. Pilot and Feasibility Studies  (2018) 4:7 Page 7 of 7
